Advertisement

Topics

Big promises? Questionable stem cell therapies marketed to heart failure patients

13:22 EDT 28 Jul 2017 | Cardiovascular Business

In a research letter published online July 24 in JAMA Internal Medicine, four physicians from the St. Louis University contacted 61 centers offering stem cell therapy, which is not approved by the FDA, to heart failure patients.

Original Article: Big promises? Questionable stem cell therapies marketed to heart failure patients

NEXT ARTICLE

More From BioPortfolio on "Big promises? Questionable stem cell therapies marketed to heart failure patients"

Quick Search
Advertisement
 

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...